Recurrent WHO Grade II Glioma
5 clinical trials · Condition
◉ Watch Recurrent WHO Grade II Glioma
| Record | Firm | Date |
|---|---|---|
| Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 Alterations (NCT05222165) | Helsinn Healthcare SA | 2021-10-01 |
| Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ Recurrent or Progressive Glioblastoma (NCT04214392) | City of Hope Medical Center | 2020-02-26 |
| BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations (NCT03914742) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2020-02-16 |
| BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas (NCT03749187) | University of California, San Francisco | 2019-04-03 |
| Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma (NCT02208362) | City of Hope Medical Center | 2015-05-18 |
Track Recurrent WHO Grade II Glioma automatically
Every clearance here is in the API, with alerts when new ones post.